CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026)
CytomX Therapeutics (CTMX) posted Change in Receivables of -$1.4 million for Q1 2026, down 455.99% on a QoQ basis from $384000.0 in Q4 2025, and down 19.18% year-over-year from -$1.7 million in Q1 2025.
CytomX Therapeutics (CTMX) Change in Receivables (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Change in Receivables history runs 13 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
- Quarterly Change in Receivables fell 19.18% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (up 88.33% YoY) and the FY2025 annual result came in at -$1.1 million, down 231.31% from the prior year.
- Change in Receivables was -$1.4 million for Q1 2026 at CytomX Therapeutics, down from $384000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $34.2 million in Q4 2022 and bottomed at -$34.9 million in Q1 2023.
- A 5-year average of -$8470.6 and a median of $232000.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 35368.04% — and 2023, when it slumped 15141.38%.
- CytomX Therapeutics' Change in Receivables stood at $34.2 million in 2022, then sank by 97.04% to $1.0 million in 2023, then sank by 124.58% to -$249000.0 in 2024, then jumped by 254.22% to $384000.0 in 2025, then slumped by 455.99% to -$1.4 million in 2026.
- Business Quant data shows CTMX's Change in Receivables at -$1.4 million in Q1 2026, $384000.0 in Q4 2025, and -$240000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Dec 31, 2025 | 384,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Sep 30, 2025 | -240,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Jun 30, 2025 | -87,000.00 |
| Mar 31, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.15 Mn |
| Dec 31, 2024 | -249,000.00 |
| Dec 31, 2024 | -249,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Jun 30, 2024 | -10.40 Mn |
| Jun 30, 2024 | -10.40 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Mar 31, 2024 | 9.75 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2023 | 1.01 Mn |